# Regeneron signs $3B manufacturing agreement with Fujifilm Diosynth in North Carolina

Regeneron has announced a new manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies to produce bulk drug product at their Holly Springs, North Carolina campus. The total investment is estimated to exceed $3 billion over a ten-year term.

- Type: Contract
- Announced: 2025-04-22
- Where: Holly Springs, North Carolina, USA, United States
- Value: $3.00B
- Status: announced
- Capacity: nearly double U.S. large-scale manufacturing capacity
- Products: biologic medicines, bulk drug product
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Regeneron Pharmaceuticals](https://endata.com/companies/84291.md)
- [Fujifilm Diosynth Biotechnologies](https://endata.com/companies/66246.md) (supplier)

## Sources

- [investor.regeneron.com](https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-new-investment-manufacturing-its-industry/), 2025-04-22: "Regeneron today announced a significant expansion of its manufacturing capacity through a new agreement with FUJIFILM Diosynth Biotechnologies to manufacture and supply bulk drug product of Regeneron’s commercial biologic medicines at their Holly Springs, North Carolina campus."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.